Guide
Mitochondrial peptides are a small but conceptually distinct group in this catalog. Rather than acting through a conventional cell-surface receptor, most work by intervening directly in mitochondrial structure or metabolism. This guide covers the shared biology and how the two flagship compounds — MOTS-c and SS-31 — differ, since they are often mentioned together despite working through entirely unrelated mechanisms.
Quick summary
- Mitochondrial dysfunction — reduced ATP output, cardiolipin damage, rising ROS — is common to aging and many chronic disease processes.
- MOTS-c is a naturally occurring signaling peptide encoded by mitochondrial DNA; it acts on the AICAR/AMPK metabolic pathway and can translocate to the nucleus.
- SS-31 (elamipretide) is a synthetic peptide that physically stabilizes cardiolipin and mitochondrial membrane architecture.
- SS-31 has FDA accelerated approval (2025) for Barth syndrome; MOTS-c has no completed human trials.
- They are not interchangeable and not established as complementary — that pairing is inference, not demonstrated synergy.
- Humanin is a third mitochondrial-derived peptide worth knowing about, though not currently in this catalog.
Why mitochondria specifically
Mitochondria generate the majority of cellular ATP through oxidative phosphorylation, a process that inevitably leaks some electrons and generates reactive oxygen species as a byproduct. Mitochondrial function is documented to decline with age across multiple measures: reduced ATP output, damage to cardiolipin (the phospholipid that organizes the inner membrane and respiratory complexes), and increased ROS production feeding back into further damage.
This decline is implicated across a wide range of conditions — sarcopenia, neurodegeneration, cardiovascular disease, and inherited mitochondrial disorders among them — which is what makes mitochondria-targeted compounds a genuinely active research area rather than a niche one.
Two different strategies
MOTS-c and SS-31 are frequently discussed in the same breath because both are described as “mitochondrial peptides,” but they intervene at different levels entirely.
MOTS-c is a naturally occurring 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene — it is the mitochondrion’s own signaling molecule, not a synthetic intervention. It acts primarily through metabolic signaling: inhibiting the folate-methionine cycle to raise AICAR, which activates AMPK, the cell’s central energy-sensing switch. Under metabolic stress it can also translocate to the nucleus and influence gene expression there, a mitochondria-to-nucleus signaling route sometimes called retrograde signaling.
SS-31 (elamipretide) is a fully synthetic aromatic-cationic tetrapeptide with no natural counterpart. It concentrates roughly a thousandfold in the inner mitochondrial membrane and binds cardiolipin directly, physically stabilizing cristae structure and reducing the electron leak that produces ROS. Its mechanism is structural rather than signaling-based.
Put simply: MOTS-c sends a metabolic message; SS-31 reinforces the physical architecture the message depends on. They are not redundant, but they are also not established as synergistic — no controlled research has tested them together.
Where the evidence actually stands
This is the point most commercial descriptions blur, and it is worth being precise about.
SS-31 has been through roughly two decades of clinical development, including large trials in mitochondrial myopathy and heart failure that failed their primary endpoints, and one narrow, hard-won FDA accelerated approval in September 2025 for Barth syndrome — an ultra-rare disease with a genetic defect in cardiolipin remodeling that matches the compound’s mechanism unusually precisely. That approval does not extend to any other condition.
MOTS-c has no completed human interventional trials of the peptide itself. The human evidence is genetic and observational — a specific mitochondrial DNA polymorphism has been associated with longevity and exercise phenotypes in some populations — alongside positive results in mouse models. A MOTS-c analog was taken into early clinical development by CohBar, but the company wound down without producing a marketed product.
These are two very different evidentiary positions, and the difference matters more than the shared “mitochondrial” label suggests.
A third peptide worth knowing: humanin
MOTS-c belongs to a small class called mitochondrial-derived peptides, alongside an earlier-discovered relative called humanin — a 24-amino-acid peptide, also mitochondrially encoded, studied for cytoprotective and anti-apoptotic effects, particularly in neurodegeneration research. It is not currently part of this catalog, but understanding that MOTS-c is one member of a broader family, rather than a singular discovery, is useful context for reading the wider literature.
Frequently asked questions
Should I choose MOTS-c or SS-31?
They are not substitutes — they address different aspects of mitochondrial function through unrelated mechanisms, and no research has directly compared or combined them. The choice depends on which mechanism is relevant to the specific research question.
Is SS-31’s FDA approval relevant to general mitochondrial research?
Only narrowly. The approval is specific to Barth syndrome, a rare genetic disease. It followed large trial failures in more common conditions and should not be read as validating broader mitochondrial or longevity claims.
What does “mitochondrial-derived peptide” mean?
A small class of peptides, including MOTS-c and humanin, encoded within mitochondrial DNA rather than nuclear DNA — a functional category discovered only in the last two decades.
References
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454.
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029–2050.
- Cobb LJ, et al. Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging. 2016.
Read our full MOTS-c breakdown → | Read our full SS-31 breakdown →
View the MOTS-c product listing → | View the SS-31 product listing →
Look up your lot Certificate of Analysis →
For laboratory and research use only. Not for human consumption. MOTS-c is not approved by any regulatory authority; elamipretide is FDA approved only for Barth syndrome under the brand name FORZINITY. This article summarizes published research for informational purposes and is not medical advice, nor a recommendation or protocol for use.
Related research compounds
Arc Peptides supplies these compounds, each third-party tested for purity and identity with a lot-specific Certificate of Analysis:
For laboratory research use only. Not for human consumption.
